Wedbush restated their outperform rating on shares of Catabasis Pharmaceuticals (NASDAQ:CATB) in a report published on Wednesday, February 14th. They currently have a $4.00 price objective on the biotechnology company’s stock, down from their previous price objective of $5.00. Wedbush also issued estimates for Catabasis Pharmaceuticals’ FY2022 earnings at $0.71 EPS.
A number of other research firms have also recently commented on CATB. Zacks Investment Research raised shares of Catabasis Pharmaceuticals from a hold rating to a buy rating and set a $1.75 price target for the company in a research note on Friday, January 26th. Citigroup upgraded shares of Catabasis Pharmaceuticals from a neutral rating to a buy rating and set a $3.00 price objective for the company in a report on Monday, November 20th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $4.82.
Catabasis Pharmaceuticals (NASDAQ:CATB) opened at $1.74 on Wednesday. Catabasis Pharmaceuticals has a 12 month low of $1.09 and a 12 month high of $3.78. The company has a market cap of $41.72 and a P/E ratio of -1.15.
A number of large investors have recently bought and sold shares of the stock. Geode Capital Management LLC raised its holdings in Catabasis Pharmaceuticals by 146.1% during the 4th quarter. Geode Capital Management LLC now owns 76,612 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 45,476 shares during the last quarter. Oppenheimer & Co. Inc. raised its holdings in Catabasis Pharmaceuticals by 40.8% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 169,000 shares of the biotechnology company’s stock valued at $358,000 after buying an additional 49,000 shares during the last quarter. Virtu KCG Holdings LLC bought a new stake in Catabasis Pharmaceuticals during the 2nd quarter valued at $271,000. Deutsche Bank AG bought a new stake in Catabasis Pharmaceuticals during the 4th quarter valued at $335,000. Finally, Wedbush Securities Inc. raised its holdings in Catabasis Pharmaceuticals by 2,368.6% during the 3rd quarter. Wedbush Securities Inc. now owns 251,802 shares of the biotechnology company’s stock valued at $534,000 after buying an additional 241,602 shares during the last quarter. Institutional investors own 32.40% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/24/wedbush-reaffirms-outperform-rating-for-catabasis-pharmaceuticals-catb.html.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.